Yufang Hu Ph.D., R.Ph
Dr. Yufang Hu received his B.S. in Pharmacy from Kaohsiung Medical University in Kaohsiung City, and his M.S. degrees and Ph.D. in Industrial Pharmacy from St. John’s University in New York City. He is a registered pharmacist as well. Before coming back to Taiwan, he had worked for the Bristol-Myers Squibb Pharmaceutical Company (New Jersey), Barr Laboratory (New Jersey), and the ImmuLogic Pharmaceutical Corporation (Boston). From 1999, he joined TTY Biopharm to build up a R&D Center from scratch, to currently include more than 60 scientists. More than 30 prescription drugs were launched through this center, including two liposomal injections. In addition, another two liposomal injections, and more four long-active depot injection products are presently under development. He has solicited and received substantial government grants for more than 3 million USD to support these two special drug delivery systems: liposome and depot injection plate forms. In 2017, he founded EnhanX Biopharm, Inc., a TTY subsidiary company, that focuses on developing special drug delivery systems.
C. Hubert Chan, M.D., Ph.D.
Vice President, Clinical And Regulatory Affairs
Dr. Chan joined PharmaEngine in February 2016. He is a board certified medical oncologist. In addition to clinical practice, he has involved in several global clinical trials. He conducted two investigator initiated trials while he was at National Health Research Institutes, Taiwan. He received his Ph.D. at University of Minnesota, USA and MD at Chung Shan Medical University, Taichung, Taiwan.
Vice President, Finance & Administration
Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taipei, Taiwan.
Senior Director, Marketing & Sales
Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taipei, Taiwan